Capsules (e.g., Of Gelatin, Of Chocolate, Etc.) Patents (Class 424/451)
-
Patent number: 10588932Abstract: The present invention relates to a use of a banana stamen extract for promoting hair growth. The banana stamen extract according to the present invention promotes gene expression of VEGF and IGF1 to enhance the proliferation level of hair follicles, so that the density of hairs grown is increased. In addition, the banana stamen extract also inhibits gene expression of SRD5A1, SRDA2 and AR to decrease hair loss, and promote the gene expression of KROX20 so as to significantly enhance hair growth.Type: GrantFiled: October 30, 2018Date of Patent: March 17, 2020Assignee: TCI CO., LTD.Inventors: Yung-Hsiang Lin, Yu-Ting Lin
-
Patent number: 10576042Abstract: The present disclosure relates to a composition of at least one predominantly positively charged polyelectrolyte polymer and at least one predominantly negatively charged polyelectrolyte polymer, a preferred composition comprises poly-L-lysine and a gellan gum, preferably a methacrylate gellan gum. The present subject-matter further relates to methods for generating composition of the present disclosure and to uses of a mixture according to the disclosure for biomedical applications such as cellular and acellular systems for tissue engineering and regenerative medicine applications or as drug delivery systems, for the treatment of several diseases namely diabetes mellitus.Type: GrantFiled: November 23, 2016Date of Patent: March 3, 2020Assignee: ASSOCIATION FOR THE ADVANCEMENT OF TISSUE ENGINEERING CELL BASED TECHNOLOGIES & THERAPIES ASSOCIAÇAOInventors: Silvia Cristina Araújo Vieira, Joaquim Miguel Antunes De Oliveira, Rui Luís Gonçalves Dos Reis, Joana Catarina Da Silva Correia
-
Patent number: 10568893Abstract: Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.Type: GrantFiled: October 1, 2015Date of Patent: February 25, 2020Assignee: BRIGHAM YOUNG UNIVERSITYInventors: Paul B. Savage, Carl Genberg
-
Patent number: 10561631Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: GrantFiled: June 11, 2015Date of Patent: February 18, 2020Assignee: Amarin Pharmaceuticals Ireland LimitedInventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
-
Patent number: 10555902Abstract: The present invention relates to a solid pharmaceutical dosage forms and methods for preparing the solid pharmaceutical dosage form that contains fingolimod or its pharmaceutically acceptable salts, conjugates or complexes thereof. The solid pharmaceutical dosage forms may rapidly disintegrates in a patient's oral cavity.Type: GrantFiled: March 12, 2018Date of Patent: February 11, 2020Assignee: Handa Pharmaceuticals LLCInventor: Fangyu Liu
-
Patent number: 10548892Abstract: Embodiments of this invention provide compositions and methods for therapeutic use of diketopiperazines including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat symptoms of Autism Spectrum Disorders and Neurodevelopmental Disorders as well as manufacture of medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.Type: GrantFiled: January 12, 2018Date of Patent: February 4, 2020Assignee: NEUREN PHARMACEUTICALS LIMITEDInventors: Lawrence Irwin Glass, Michael John Bickerdike, Michael Frederick Snape, Patricia Perez De Cogram
-
Patent number: 10537551Abstract: The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.Type: GrantFiled: August 27, 2018Date of Patent: January 21, 2020Assignee: Saniona A/SInventors: Peter G. Nielsen, Mikael S. Thomsen, Bent Højgaard
-
Patent number: 10525033Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.Type: GrantFiled: August 20, 2018Date of Patent: January 7, 2020Assignee: Acacia Pharma LimitedInventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
-
Patent number: 10512625Abstract: A topical pharmaceutical composition containing diacerein and/or its analogs is provided. Also provided is a method for treating various diseases using this topical pharmaceutical composition.Type: GrantFiled: December 6, 2018Date of Patent: December 24, 2019Assignee: TWI BIOTECHNOLOGY, INC.Inventors: Chih-Kuang Chen, Jing-Yi Lee, Wei-Shu Lu, Carl Oscar Brown, III
-
Patent number: 10507181Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.Type: GrantFiled: June 18, 2019Date of Patent: December 17, 2019Assignee: Crititech, Inc.Inventors: Michael Baltezor, Matthew McClorey, William Johnston, Gere S. diZerega, James Verco
-
Patent number: 10493036Abstract: A capsule excellent in enteric property with the assumption that gelatin is used as a main base material of the capsule coating. An alkali-treated gelatin and carrageenan are contained as base materials of the capsule coating. In the gastric (aqueous) environment, the alkali-treated gelatin which is positively (+) charged coexists with the carrageenan which is negatively (?) charged, and amino groups (NH4+) in the gelatin react with sulfate groups (SO3?) in the carrageenan so that the capsule coating is insolubilized. On the other hand, in the intestinal (aqueous) environment, the alkali-treated gelatin which is negatively (?) charged coexists with the carrageenan which is negatively (?) charged, and the amino groups (NH4+) in the gelatin are repulsive to the sulfate groups (SO3?) in the carrageenan so that the capsule coating quickly disintegrates and dissolves.Type: GrantFiled: August 10, 2016Date of Patent: December 3, 2019Assignee: SUNSHO PHARMACEUTICAL CO. LTDInventors: Takayuki Fukasawa, Kenichi Koyama, Tomoya Suzuki
-
Patent number: 10493048Abstract: Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate.Type: GrantFiled: September 7, 2016Date of Patent: December 3, 2019Assignee: Neurocentria, Inc.Inventors: Guosong Liu, Fei Mao, Qifeng Sun
-
Patent number: 10487145Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: June 24, 2016Date of Patent: November 26, 2019Assignee: Rani Therapeutics, LLCInventor: Mir Imran
-
Patent number: 10485758Abstract: An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.Type: GrantFiled: June 2, 2015Date of Patent: November 26, 2019Assignee: Clexio Biosciences Ltd.Inventors: Avshalom Ben Menachem, Ilan Zalit
-
Patent number: 10485861Abstract: Provided herein are new compositions including an inactivated pathogen and one or more adjuvant-loaded polymeric nanoparticles, wherein the adjuvant-loaded nanoparticles are bound to the inactivated pathogen. These compositions are useful for preventing and/or treating diseases caused by the specific pathogens, especially when administered to a subject's mucosal membranes.Type: GrantFiled: March 14, 2014Date of Patent: November 26, 2019Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Georg Stary, Aleksandar Filip Radovic-Moreno, Pamela A. Basto, Michael N. Starnbach, Robert S. Langer, Omid C. Farokhzad, Ulrich Von Andrian
-
Patent number: 10470987Abstract: Compositions allowing the stimulation of hyaluronic acid synthesis via an increase in has-2 expression and their use in the treatment of conditions related to a decrease in hyaluronic acid synthesis.Type: GrantFiled: June 5, 2015Date of Patent: November 12, 2019Assignees: TOMCAT INTERNATIONAL LIMITED, President and Fellows of Harvard CollegeInventors: Bertrand Thomas, Mathilde Thomas, David Sinclair
-
Patent number: 10470478Abstract: An protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol and/or other spirits serving as an entertaining and novel non-beverage method of consuming alcohol. The article of manufacture encapsulates ethyl alcohol and/or other spirits in the amorphous regions of the complex macromolecular structure releasing it only upon chewing and exposure to the environment of the oral cavity. The article of manufacture is stable and capable of retaining shape and form for extended periods of time at ambient temperature allowing for relatively low-cost commercial manufacture and distribution.Type: GrantFiled: April 12, 2012Date of Patent: November 12, 2019Assignee: CURE PHARMACEUTICAL CORPORATIONInventors: Margaret Teresa Thomas Virgallito, Joshua Alan Held
-
Patent number: 10463739Abstract: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.Type: GrantFiled: December 22, 2011Date of Patent: November 5, 2019Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Gunther Berndl, Juergen Weis, Dietrich Granzow, Bernd Liepold, Ute Lander, Ulrich Westedt
-
Patent number: 10449148Abstract: Compositions that can be used to improve human health, and in particular brain health are provided. In some embodiments the composition comprises Inositol, N-Acetyl L-Tyrosine, pyrroloquinoline quinone (PQQ), Choline bitartrate, L-Theanine and Acetyl-L-Carnitine. The compositions may be administered to a subject, for example in the form of a liquid drink, to improve brain health.Type: GrantFiled: October 6, 2016Date of Patent: October 22, 2019Assignee: BRAINGEAR ENTERPRISES, INC.Inventors: Patricia Gutierrez, Christina Beer
-
Patent number: 10441591Abstract: This invention discloses uses for etonogestrel in preparing anti-prostate cancer products. This invention provides uses for etonogestrel in preparing anti-prostate cancer products. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug etonogestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that etonogestrel has a new use as an anti-prostate cancer medication, thus achieving a new purpose for an old drug.Type: GrantFiled: June 30, 2015Date of Patent: October 15, 2019Assignee: SHANGHAI JIAO TONG UNIVERSITYInventors: Yongyong Shi, Zhijian Song
-
Patent number: 10434139Abstract: An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.Type: GrantFiled: January 19, 2017Date of Patent: October 8, 2019Assignee: Sublimity Therapeutics LimitedInventor: Ivan Coulter
-
Patent number: 10434140Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.Type: GrantFiled: May 16, 2017Date of Patent: October 8, 2019Assignee: Sublimity Therapeutics LimitedInventor: Ivan Coulter
-
Patent number: 10432604Abstract: A computer-implemented system and method for pool-based identity authentication for service access without use of stored credentials is disclosed. The method in an example embodiment includes providing provisioning information for storage in a provisioning repository; receiving a service request from a service consumer, the service request including requestor identifying information; generating an authentication request to send to an authentication authority, the authentication request including requestor identifying information; receiving validation of an authenticated service request from the authentication authority; and providing the requested service to the service consumer.Type: GrantFiled: September 6, 2018Date of Patent: October 1, 2019Assignee: eBay Inc.Inventors: Raju Venkata Kolluru, Michael Dean Kleinpeter
-
Patent number: 10420773Abstract: Methods of treating developmental disorders and/or seizure disorders with etifoxine, a deuterated analog of etifoxine, or a pharmaceutically acceptable salt, solvate, or prodrug thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder and/or seizure disorder.Type: GrantFiled: April 24, 2018Date of Patent: September 24, 2019Assignee: OVID THERAPEUTICS INC.Inventor: Matthew During
-
Patent number: 10413558Abstract: A pharmaceutical composition or kit of parts comprising at least three ingredients from a HMG-CoA reductase inhibitor, a leukotriene antagonist, a proton pump inhibitor, melatonin or a melatonin receptor agonist, a bioavailable preparation of a curcuminoid, a calciferol derivative, a compound from the group consisting of metformin and phenformin, valproate, minocycline and chloroquine and one or more pharmaceutically acceptable carriers or excipients.Type: GrantFiled: October 19, 2015Date of Patent: September 17, 2019Assignee: TARGETED THERAPIES RESEARCH AND CONSULTING CENTER SPRLInventor: Marc Zeicher
-
Patent number: 10398746Abstract: An edible oral film strip dosage form containing an unpalatable basic active pharmaceutical ingredient and an ion exchange resin as a primary taste masking agent, along with an optional acidic agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.Type: GrantFiled: January 31, 2017Date of Patent: September 3, 2019Assignee: LTS Lohmann Therapie-Systeme AGInventors: Michael Li, Markus Krumme
-
Patent number: 10383826Abstract: The present invention provides an apparatus and process for making softgel capsules having incorporated therein other solid dosage forms selected from the group consisting of pellets, smaller capsules, smaller tablets, sustained release solid dosage forms, immediate release solid dosage forms, extended release solid dosage forms and zero order release solid dosage forms, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies having means for suction; (d) a liquid fill system; (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) two lateral dispensing devices said lateral dispensing devices including hoppers having said solid dosage forms, channel guides for transporting said solid dosage forms and a grasping claw for dispensing said solid dosage form into the softgel pocket formed in the rotary dies.Type: GrantFiled: September 5, 2016Date of Patent: August 20, 2019Assignee: PROCAPS SAInventors: Carlos Salazar Altamar, Gustavo Anaya, Braulio Teran, Newman Aguas Navarro, Wilmer Herrera
-
Patent number: 10376501Abstract: Disclosed herein are pharmaceutically acceptable complex formulations comprising complexes of Lumacaftor, or a salt, or derivative thereof together with complexation agents and, optionally, pharmaceutically acceptable excipients; processes for the preparation thereof and pharmaceutical compositions containing them. The complex formulations have improved dissolution and permeability in fasted and fed state simulation that is expected to deliver full absorption and the elimination of the food effect.Type: GrantFiled: April 25, 2017Date of Patent: August 13, 2019Assignee: Druggability Technologies IP Holdco LimitedInventors: Richárd Balázs Kárpáti, Betti Szabóné Ordasi, Orsolya Basa-Dénes, Erzsébet Réka Angi, Tamás Jordán, László Molnár, Hristos Glavinas, Zsolt Ötvös, Genovéva Filipcsei
-
Patent number: 10369340Abstract: Devices and methods for administering a therapeutic agent, including an implantable delivery device. Exemplary embodiments include a reservoir in fluid communication with a channeled member, and a compound including the therapeutic agent and a solubilizer disposed within the reservoir.Type: GrantFiled: August 11, 2014Date of Patent: August 6, 2019Assignee: NANOMEDICAL SYSTEMS, INC.Inventors: Michael Crowley, Randy Goodall, Lee Hudson
-
Patent number: 10369111Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not 5 limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically 10 diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a 15 mammal, most specifically the ileum and/or right colon of a human subject.Type: GrantFiled: January 18, 2018Date of Patent: August 6, 2019Assignee: Therabiome, LLCInventors: Mohan Kabadi, Jerome J. Schentag
-
Patent number: 10363220Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.Type: GrantFiled: June 3, 2016Date of Patent: July 30, 2019Assignee: Triastek, Inc.Inventor: Xiaoling Li
-
Patent number: 10357455Abstract: A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.Type: GrantFiled: July 27, 2018Date of Patent: July 23, 2019Assignee: Bend Research, Inc.Inventors: Michael E. Perlman, Ravi M. Shanker, Walter C. Babcock, Dwayne Thomas Friesen, Mark D. Rabenstein, Daniel Tod Smithey
-
Patent number: 10350296Abstract: Chewable gelatin formulations that include a bovine gelatin and a fish gelatin.Type: GrantFiled: July 22, 2014Date of Patent: July 16, 2019Assignee: Aspire PharmaceuticalsInventors: Madhav Pai, Ritesh Patel
-
Patent number: 10347158Abstract: A dissolvable produce washing label includes a dissolvable facestock impregnated with a produce cleanser; an adhesive layer; and a coating to seal and protect from water and humidity. When rubbed and washed with water by the end user the top coating wears and breaks to expose the dissolvable substrate, thereby dissolving the facestock and releasing the produce wash.Type: GrantFiled: November 21, 2012Date of Patent: July 9, 2019Inventor: Scott Amron
-
Patent number: 10342848Abstract: This invention provides a method of colonic cleansing.Type: GrantFiled: December 16, 2016Date of Patent: July 9, 2019Assignee: BAUSCH HEALTH IRELAND LIMITEDInventors: Dennis Riff, Gary S. Jacob, Kunwar Shailubhai, Patrick H. Griffin
-
Patent number: 10335371Abstract: The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.Type: GrantFiled: February 17, 2016Date of Patent: July 2, 2019Assignees: Universiteit Gent, Orotech NVInventors: Jean-Paul Remon, Chris Vervaet, Brenda Vermeulen
-
Patent number: 10336817Abstract: A therapeutic composition of camel milk can include an herbal composition having solid material or liquid extracts from the solid material of at least one of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The solid material may include one or more of parts or the whole of the stem, the bark, the flowers and the roots of one or more, but preferably all of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The therapeutic composition can include camel milk, alone, or in combination with the herbal composition. The camel milk can be HIV-immunized camel milk. The HIV-immunized camel milk can be obtained by immunizing a camel against HIV by administering to the camel the modified DNA plasmids of SEQ. ID No.: 3 and SEQ ID No.: 4 and obtaining the milk from the immunized camel.Type: GrantFiled: August 25, 2017Date of Patent: July 2, 2019Assignee: Sultan Qaboos UniversityInventors: Sidgi Syed Anwer Abdo Hasson, Ali A. H. Al-Jabri
-
Patent number: 10328087Abstract: Compositions and methods for the solubilization of steroid hormones are disclosed.Type: GrantFiled: July 22, 2016Date of Patent: June 25, 2019Assignee: TherapeuticsMD, Inc.Inventors: Thorsteinn Thorsteinsson, Frederick D. Sancilio, Brian A. Bernick, Julia M. Amadio
-
Patent number: 10328038Abstract: The present technology provides siderophore-polymer conjugates that enhance the sensitivity of bacteria to antibiotics, e.g., Pseudomonas, P. aeruginosa, Acinetobacter, and A. baumannii.Methods of preparing and using such conjugates to treat bacterial infections are disclosed.Type: GrantFiled: August 24, 2017Date of Patent: June 25, 2019Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: May Xiong, Max Purro
-
Patent number: 10314812Abstract: The present invention is directed to compositions comprising physiologically active phenolic compounds and methods for making and using the same. In particular embodiments, the compositions described herein include suspension formulations including a physiologically active phenolic compound provided as a nanoparticulate material and dispersed within an edible lipid.Type: GrantFiled: February 28, 2018Date of Patent: June 11, 2019Assignee: Humanetics CorporationInventors: David C. Egberg, Michael D. Kaytor, John C. Dykstra
-
Patent number: 10314868Abstract: Suppository compositions are provided combining a pharmaceutically acceptable matrix material that is solid outside of the human body and in a dry environment, but which melts at body temperature; and apple cider vinegar and one or more species of probiotic bacteria dispersed within the matrix material; wherein the matrix material contains a mixture of fatty acids that are solid at room temperature. Methods for supplementing and nourishing the microbiome of the rectum of a male or female and the microbiome of the vagina of a female are also disclosed. Oral dosage forms of the compositions of the present invention are also provided.Type: GrantFiled: March 8, 2017Date of Patent: June 11, 2019Inventor: Deborah L. Lynch
-
Patent number: 10307579Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: December 5, 2017Date of Patent: June 4, 2019Assignee: Rani Therapeutics, LLCInventor: Mir Imran
-
Patent number: 10307385Abstract: A gelling formulation containing ketamine or a pharmaceutically acceptable salt thereof in water, a poloxamer and one or more pharmaceutically acceptable mucoadhesive agents is provided. Also provided is a method of using the formulation for pain treatment.Type: GrantFiled: August 30, 2013Date of Patent: June 4, 2019Assignee: Assistance Publique-Hopitaux de ParisInventors: Vincent Boudy, Annick Tibi, Benoît D'Hayer, Marie-Caroline Husson, Sandrine Graff De Faget
-
Patent number: 10300020Abstract: The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule.Type: GrantFiled: November 14, 2014Date of Patent: May 28, 2019Assignee: WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITEDInventors: Julie Economou, Shehla Uraizee
-
Patent number: 10302660Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.Type: GrantFiled: November 21, 2016Date of Patent: May 28, 2019Assignees: OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LTD.Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
-
Patent number: 10292939Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.Type: GrantFiled: September 4, 2018Date of Patent: May 21, 2019Assignee: Purdue Pharma L.P.Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
-
Patent number: 10294019Abstract: A system for brewing medicinal beverages, using a cartridge-based beverage formation apparatus, comprises a cartridge containing a beverage composition comprising a mixture of one or more water-soluble active pharmacological treatment agents, such as pain relievers, cold medications, sleeping aids, laxatives, stimulants, or vitamins, and one or more water-soluble non-pharmacological constituents, which can include water-soluble carbohydrates, proteins, alcohols, sweetening, flavoring and coloring agents, anti-caking agents, buffering and acidifying agents, surfactants, thickening and stabilizing agents, antioxidants and/or preservatives.Type: GrantFiled: August 17, 2016Date of Patent: May 21, 2019Assignee: Raritan Pharmaceuticals Inc.Inventor: Vin Nayak
-
Patent number: 10294337Abstract: A process for preparing poly(lactide-co-glycolide) copolymer particles with an average particle size in the range of 50-800 nm includes transferring a mixture of poly(lactide-co-glycolide) copolymer, ethanol and carbon dioxide from a first reactor into a second reactor under rapid reduction of the pressure and expansion with phase separation into a gas phase, an ethanol aerosol and an ethanolic suspension containing poly(lactide-co-glycolide) copolymer particles, removing the carbon dioxide gas and the ethanol aerosol from the second reactor, and obtaining the poly(glycolide-co-lactide) copolymer particles in the form of an ethanolic suspension or in dry form from the second reactor.Type: GrantFiled: June 21, 2016Date of Patent: May 21, 2019Assignee: Evonik Röhm GmbHInventors: Andreas Kirchner, Rosario Lizio, Markus Rolf Rossmeissl, Wolfgang Luley, Johannes Vorholz, Silko Grimm, Marc Schneider
-
Patent number: 10287401Abstract: The present disclosure is directed to polymer and polymer conjugate-based nanoparticle delivery systems for delivering biological agents, and methods of making and using these compositions. Certain embodiments of the present disclosure provide polymers comprising alternating charged and uncharged segments comprising one or more of the following structural units of Formula (I) or Formula (II) or Formula (III): wherein is an uncharged segment comprising polyalkylene glycol; and B is a cationically charged segment comprising at least one polyhydroxy linkage.Type: GrantFiled: June 13, 2016Date of Patent: May 14, 2019Assignee: California Institute of TechnologyInventors: Mark E. Davis, Dorothy Pan
-
Patent number: 10272164Abstract: Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.Type: GrantFiled: June 5, 2017Date of Patent: April 30, 2019Assignee: Incept, LLCInventors: Patrick Campbell, Amarpreet S. Sawhney